Compare Garmin Ltd. (GRMN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Recursion Pharmaceuticals Inc — how do they compare? Garmin Ltd. trades at $250.38 (market cap $46.62B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.75B). The key difference: Garmin Ltd. is far larger — about 26.6× Recursion Pharmaceuticals Inc's market cap, and Garmin Ltd. pays a 1.74% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GRMN | RXRX | |
|---|---|---|
Market Cap | $46.62B | $1.75B |
Sector | Technology | Health |
52-Week High | $267.52 | $6.79 |
52-Week Low | $187.10 | $2.84 |
Enterprise Value | $44.09B | $1.17B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $247.96, up 2.72% on the day, with a neutral technical outlook and mixed earnings history including recent beats. Revenue growth is strong, reaching $7.25B in 2025, with robust profitability margins. Recent news highlights product innovations in aviation and marine electronics, supporting growth prospects. The stock is near its consensus price target of $281.50, indicating moderate upside potential from current levels.
The outlook for GRMN is cautiously optimistic, driven by solid fundamentals and innovation, but tempered by high valuation ratios and a majority hold rating from analysts. Key risks include competitive pressures and market volatility, while institutional sentiment remains mixed with limited insider activity noted.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
